Research
Hormonal
Neither circulating plasma IL-6 nor skeletal muscle IL-6 mRNA are predictors of insulin resistance in patients with type 2 diabetes.
Practitioners should not rely on IL-6 levels as indicators of insulin resistance in type 2 diabetes.
StrongRefutesmedium confidence
our data demonstrated that neither circulating IL-6 nor skeletal muscle IL-6 mRNA are predictors of insulin resistance in patients with type 2 diabetes.
Why this rating
Based on study design from abstract.
Source
NEITHER CIRCULATING IL-6 NOR SKELETAL MUSCLE IL-6 mRNA ARE PREDICTORS OF INSULIN RESISTANCE IN HUMANS
Andrew L. Carey et al. · Medicine & Science in Sports & Exercise · 2003
DOI 10.1097/00005768-200305001-00865
cross-sectional · n=23
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →